Quiñones-Aguilar Sandra, Sauri-Suárez Sergio, Alcaraz-Estrada Sofía Lizeth, García Silvia
Neurologist, Neurology Department, National Medical Center '20 de Noviembre' ISSSTE, México City, Mexico.
Division of Genomic Medicine, National Medical Center '20 de Noviembre' ISSSTE, México City, Mexico.
Neuro Endocrinol Lett. 2019 Dec;40(5):222-226.
One of the most dreaded complications in Multiple Sclerosis (MS) patients treated with natalizumab is the appearance of the Progressive Multifocal Leukoencephalopathy (PML). A 54-year-old Mexican woman diagnosed eight years before with MS, received natalizumab for the last three years. The patient developed PLM that was confirmed by clinical, radiological, blood and CSF tests. Her treatment included methylprednisolone, plasmapheresis, immunoglobulin and mirtazapine. Risks, causes, treatments, preventive measures and opportune diagnosis for these patients are analyzed in this report.
在用那他珠单抗治疗的多发性硬化症（MS）患者中，最可怕的并发症之一是进行性多灶性白质脑病（PML）的出现。一名54岁的墨西哥女性八年前被诊断为MS，在过去三年中接受了那他珠单抗治疗。该患者发生了PML，经临床、放射学、血液和脑脊液检查确诊。她的治疗包括甲泼尼龙、血浆置换、免疫球蛋白和米氮平。本报告分析了这些患者的风险、病因、治疗方法、预防措施和及时诊断。
